Oncology Practice Management Issues


August 2017, Vol 7, No 8

A New Prior Authorization Decision-Support Tool Can Reduce the Costs of Cancer Treatment

Dana Taylor

Reimbursement

Unless the costs of cancer care are reduced significantly, it is estimated that by 2028, the combination of patients’ health insurance premium costs plus out-of-pocket expenses will be the same as the average US household income. Cancer drug costs are escalating at an even faster rate, at least in part because of accelerated new approvals by the FDA and higher drug unit costs. [ Read More ]

Rising Costs of Cancer Drugs Explored

Phoebe Starr

Value-Based Care

San Antonio, TX—The cost of cancer drugs has increased exponentially over the past decade, straining the healthcare system and patients’ ability to pay for them. Cancer treatments that cost $150,000 or more are not unusual in the United States. Pharmaceutical manufacturers continue to increase drug prices through packaging maneuvers and the use of artificial expiration dates, and as a result, some old drugs “in new clothing” remain expensive. [ Read More ]

FDA News – August 2017

FDA News

  • Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
  • Rituximab Combination Now Approved in 3 Blood Cancers
  • First FDA-Approved Test to Help Detect Several Leukemias and Lymphomas
  • DigniCap Cooling System Receives Expanded Indication for Use in Patients with Solid Tumors
  • Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL
  • First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell ALL in Children and Young Adults
  • Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
[ Read More ]

Low Use of Genomic Tests Among Oncologists for Lung and Colorectal Cancers

Laura Morgan

Genetic Testing

The introduction of targeted cancer drugs has revolutionized cancer treatment, especially in patients with colorectal cancer (CRC) or non–small-cell lung cancer (NSCLC). These drugs have been accompanied by genomic assays that test for certain mutations, such as ALK, KRAS, BRAF, or EGFR, which often help guide cancer treatment decisions by identifying patients who would benefit most from certain therapies over others. However, there are few data regarding the real-world use of genomic tests among oncologists for these cancers. [ Read More ]